Skip to main content
Top
Published in: World Journal of Surgery 2/2015

01-02-2015 | Original Scientific Report

Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma

Authors: Marco Scarpa, Giulia Noaro, Luca Saadeh, Francesco Cavallin, Matteo Cagol, Rita Alfieri, Mario Plebani, Carlo Castoro

Published in: World Journal of Surgery | Issue 2/2015

Login to get access

Abstract

Background

Esophagectomy is contraindicated in case of advanced cancer (i.e., carcinomatosis, distant metastasis, and invasion of other organs). In some cases, preoperative imaging may fail to identify advanced neoplasm and esophagectomy is inappropriately planned. The aim of the study was to identify preoperative biomarkers of occult advanced disease that force surgeons to abort the planned esophagectomy.

Methods

From 2008 to 2014, 244 consecutive patients were taken to the operative room to have esophagectomy for cancer in our department. All of them had blood test at admission and their preoperative biomarker data were retrieved. Their medical history was collected and the intraoperative findings and outcome were recorded. Non parametric tests, multiple regression analysis, and ROC curves analysis were performed.

Results

In our study group, 14 (5.7 %) patients, scheduled for esophagectomy, were discovered to have occult advanced disease at laparotomy/laparoscopy or at thoracotomy. Six of them had peritoneal carcinomatosis, three had advanced tumor invading other organs, three had small liver metastasis, and two pleural carcinomatosis. In all these cases, esophagectomy was aborted and a feeding jejunostomy was placed. In patients with unresectable esophageal cancer, CA19.9 and CEA serum levels were significantly higher than patients who could have esophagectomy (p < 0.001 and p = 0.003, respectively). CA19.9 and CEA resulted to be accurate biomarkers of occult advanced disease (AUC = 85 %, p < 0.001 and AUC = 73 %, p = 0.002, respectively).

Conclusions

Preoperative CEA and CA19.9 serum levels should be taken in consideration when evaluating patients candidate to esophagectomy for esophageal cancer to prevent inappropriate laparotomy or thoracotomy. If any doubt arises minimally invasive exploration is warranted.
Literature
1.
go back to reference Donahue JM, Nichols FC, Li Z et al (2009) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87(2):392–398PubMedCentralPubMedCrossRef Donahue JM, Nichols FC, Li Z et al (2009) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87(2):392–398PubMedCentralPubMedCrossRef
2.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, Cross Group et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084PubMedCrossRef van Hagen P, Hulshof MC, van Lanschot JJ, Cross Group et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084PubMedCrossRef
3.
go back to reference Lin CC, Hsu CH, Cheng JC et al (2007) Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 18:93–98PubMedCrossRef Lin CC, Hsu CH, Cheng JC et al (2007) Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 18:93–98PubMedCrossRef
4.
go back to reference Wouters MW, Gooiker GA, van Sandick JW et al (2012) The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer 118(7):1754–1763PubMedCrossRef Wouters MW, Gooiker GA, van Sandick JW et al (2012) The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer 118(7):1754–1763PubMedCrossRef
5.
go back to reference Bailey SH, Bull DA, Harpole DH et al (2003) Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 75(1):217–222PubMedCrossRef Bailey SH, Bull DA, Harpole DH et al (2003) Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 75(1):217–222PubMedCrossRef
6.
go back to reference Blackstock AW, Farmer MR, Lovato J et al (2006) A prospective evaluation of the impact of 18-F-fluorodeoxy-d-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 64:455–460PubMedCrossRef Blackstock AW, Farmer MR, Lovato J et al (2006) A prospective evaluation of the impact of 18-F-fluorodeoxy-d-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 64:455–460PubMedCrossRef
7.
go back to reference Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW (2010) Outcomes of patients with esophageal cancer staged with [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28(31):4714–4721. doi:10.1200/JCO.2010.30.7702 PubMedCentralPubMedCrossRef Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW (2010) Outcomes of patients with esophageal cancer staged with [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28(31):4714–4721. doi:10.​1200/​JCO.​2010.​30.​7702 PubMedCentralPubMedCrossRef
9.
go back to reference Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA (1998) The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35(Pt 1):99–103PubMedCrossRef Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA (1998) The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35(Pt 1):99–103PubMedCrossRef
10.
go back to reference Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39(6):718–727. doi:10.1016/S0959-8049(02)00811-0 PubMedCrossRef Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39(6):718–727. doi:10.​1016/​S0959-8049(02)00811-0 PubMedCrossRef
11.
go back to reference Perkins G, Slater E, Sanders G, Prichard J (2003) Serum tumor markers. Am Fam Physician 68(6):1075–1082PubMed Perkins G, Slater E, Sanders G, Prichard J (2003) Serum tumor markers. Am Fam Physician 68(6):1075–1082PubMed
13.
go back to reference Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327. doi:10.1200/JCO.2006.08.2644 PubMedCrossRef Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327. doi:10.​1200/​JCO.​2006.​08.​2644 PubMedCrossRef
14.
go back to reference Sobin L, Wittekind C, UICC (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York Sobin L, Wittekind C, UICC (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York
16.
go back to reference Ruol A, Portale G, Castoro C, Merigliano S, Cavallin F, Battaglia G, Michieletto S, Ancona E (2007) Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg 32(3):445–448 Epub 2007 Jul 23PubMedCrossRef Ruol A, Portale G, Castoro C, Merigliano S, Cavallin F, Battaglia G, Michieletto S, Ancona E (2007) Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg 32(3):445–448 Epub 2007 Jul 23PubMedCrossRef
17.
go back to reference Holscher A, Schroder W, Bollschweiler E, Beckurts K, Schneider P (2003) How safe is high intrathoracic esophagogastrostomy? Chirurg 74:726–733PubMedCrossRef Holscher A, Schroder W, Bollschweiler E, Beckurts K, Schneider P (2003) How safe is high intrathoracic esophagogastrostomy? Chirurg 74:726–733PubMedCrossRef
18.
go back to reference Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics. CA Cancer J Clin. 53(1):5–26PubMedCrossRef Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics. CA Cancer J Clin. 53(1):5–26PubMedCrossRef
19.
20.
go back to reference Pultrum BB, van Westreenen HL, Mulder NH, van Dullemen HM, Plukker JT (2006) Outcome of palliative care regimens in patients with advanced oesophageal cancer detected during explorative surgery. Anticancer Res 26(3B):2289–2293PubMed Pultrum BB, van Westreenen HL, Mulder NH, van Dullemen HM, Plukker JT (2006) Outcome of palliative care regimens in patients with advanced oesophageal cancer detected during explorative surgery. Anticancer Res 26(3B):2289–2293PubMed
21.
go back to reference Mortensen MB, Fristrup CW, Ainsworth AP, Pless T, Nielsen HO, Hovendal C (2006) Combined preoperative endoscopic and laparoscopic ultrasonography for prediction of R0 resection in upper gastrointestinal tract cancer. Br J Surg 93(6):720–725PubMedCrossRef Mortensen MB, Fristrup CW, Ainsworth AP, Pless T, Nielsen HO, Hovendal C (2006) Combined preoperative endoscopic and laparoscopic ultrasonography for prediction of R0 resection in upper gastrointestinal tract cancer. Br J Surg 93(6):720–725PubMedCrossRef
22.
go back to reference Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58(1):24–38PubMedCrossRef Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58(1):24–38PubMedCrossRef
23.
go back to reference Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S (1998) CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 11(1):35–39PubMed Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S (1998) CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 11(1):35–39PubMed
24.
go back to reference Mortensen MB, Edwin B, Hünerbein M, Liedman B, Nielsen HO, Hovendal C (2007) Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: an international multicenter study. Surg Endosc 21(3):431–438PubMedCrossRef Mortensen MB, Edwin B, Hünerbein M, Liedman B, Nielsen HO, Hovendal C (2007) Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: an international multicenter study. Surg Endosc 21(3):431–438PubMedCrossRef
25.
go back to reference Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol 91(1):49–53PubMed Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol 91(1):49–53PubMed
27.
go back to reference Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K (2007) Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 14(6):539–544PubMedCrossRef Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K (2007) Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 14(6):539–544PubMedCrossRef
Metadata
Title
Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma
Authors
Marco Scarpa
Giulia Noaro
Luca Saadeh
Francesco Cavallin
Matteo Cagol
Rita Alfieri
Mario Plebani
Carlo Castoro
Publication date
01-02-2015
Publisher
Springer US
Published in
World Journal of Surgery / Issue 2/2015
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2835-1

Other articles of this Issue 2/2015

World Journal of Surgery 2/2015 Go to the issue